CYCN Cyclerion Therapeutics

Cyclerion to Present at the Evercore ISI 2nd Annual HealthCONx Conference

Cyclerion to Present at the Evercore ISI 2nd Annual HealthCONx Conference

CAMBRIDGE, Mass., Nov. 27, 2019 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company focused on the development of soluble guanylate cyclase (sGC) stimulators for the treatment of serious and orphan diseases, today announced it will present at the Evercore ISI 2nd Annual HealthCONx Conference on Tuesday, December 3, 2019, at 11:20 a.m. ET at the Four Seasons Hotel, Boston.

A live webcast of the presentation can be accessed at . An archived replay of the webcast will be available for approximately 90 days following the presentation.

About Cyclerion Therapeutics

Cyclerion Therapeutics is a clinical-stage biopharmaceutical company harnessing the power of soluble guanylate cyclase (sGC) pharmacology to discover, develop and commercialize breakthrough treatments for serious and orphan diseases. Cyclerion is advancing its portfolio of differentiated sGC stimulator programs with distinct pharmacologic and biodistribution properties that are uniquely designed to target tissues of greatest relevance to the diseases they are intended to treat. These programs include praliciguat which recently completed Phase 2 studies and which the company intends to out-license for further development in diabetic nephropathy, olinciguat in Phase 2 development for sickle cell disease, IW-6463 in Phase 1 development for serious and orphan central nervous system diseases, and two preclinical programs targeting serious liver and lung diseases, respectively.

For more information about Cyclerion, please visit and follow us on Twitter () and LinkedIn ().

Contact

Carlo Tanzi, Ph.D.

Kendall Investor Relations

617-914-0008

 

EN
27/11/2019

Underlying

CYCNCyclerion Therapeutics

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Cyclerion Therapeutics

 PRESS RELEASE
Free
CYCN Cyclerion Thera...

Cyclerion Announces Transformational Relaunch as a Neuropsychiatric Co...

Cyclerion Announces Transformational Relaunch as a Neuropsychiatric Company – Cyclerion Relaunches, Advancing a Phase 2–Ready Program for Millions Living with Treatment-Resistant Depression Through MIT License Agreement – – Webcast to be held September 24, 2025 at 10:30 a.m. ET – CAMBRIDGE, Mass., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. today announced that it has entered into a licensing agreement with the Massachusetts Institute of Technology (“MIT”), securing the intellectual property that will serve as the cornerstone of its strategic relaunch. This agreement...

September 23, 2025 1 EN
 PRESS RELEASE
Free
CYCN Cyclerion Thera...

Cyclerion’s sGC Stimulator Portfolio Generates Revenues to Enable Comp...

Cyclerion’s sGC Stimulator Portfolio Generates Revenues to Enable Company Growth Cyclerion Has Renegotiated Praliciguat License Agreement to Obtain Upfront and Near-Term Payments as well as Entered into a License Option Agreement for Olinciguat CAMBRIDGE, Mass., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), today announced an update on its progress in catalyzing the Company’s next stage of growth. The Company is leveraging its legacy soluble guanylate cyclase (sGC) stimulator assets to generate near-term revenues which will be used to implement its strat...

December 17, 2024 1 EN
 PRESS RELEASE
Free
CYCN Cyclerion Thera...

Regina Graul, Ph.D., Promoted to Chief Executive Officer

Regina Graul, Ph.D., Promoted to Chief Executive Officer CAMBRIDGE, Mass., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), today announced that Regina Graul, Ph.D., has been promoted to Chief Executive Officer, President, and member of the Board of Directors. Since Dr. Graul joined Cyclerion as President in early December 2023, she has strengthened all aspects of the company. She has been working closely with the Board of Directors to prioritize building shareholder value by reducing Cyclerion’s operating costs while leading a world-class search and evaluati...

August 7, 2024 1 EN
 PRESS RELEASE
Free
CYCN Cyclerion Thera...

Cyclerion Appoints Regina Graul, Ph.D., as President

Cyclerion Appoints Regina Graul, Ph.D., as President – Dr. Graul will lead the rebuild of Cyclerion, bringing more than two decades of drug making experience, R&D portfolio leadership, and a deep expertise in company strategy – – Peter Hecht, Ph.D., will continue to work closely with Cyclerion leadership as a strategic consultant and longstanding board member; steps down from CEO role – CAMBRIDGE, Mass., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a biopharmaceutical company on a mission to develop treatments for serious diseases, today announced that ...

December 4, 2023 1 EN
 PRESS RELEASE
Free
CYCN Cyclerion Thera...

Cyclerion Strengthens Board of Directors with Experienced Company Buil...

Cyclerion Strengthens Board of Directors with Experienced Company Builder and Cutting-edge Innovator - Dina Katabi, Ph.D.: World leader in healthcare AI applications at MIT; inventor of groundbreaking wireless devices for passive assessment of symptoms, behavior, and treatment responses in neurological and psychiatric disorders - Michael Higgins: Seasoned biopharma executive possessing business and financial acumen with CEO and extensive board experience; former entrepreneur-in-residence at Polaris Partners with a track record of launching successful companies CAMBRIDGE, Mass., Nov. 30,...

November 30, 2023 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch